Bruno P Coudert

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial
    Bruno P Coudert
    Department of Oncology, CAC G F Leclerc and IFR 100, Dijon, France
    J Clin Oncol 25:2678-84. 2007
  2. ncbi Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial
    B P Coudert
    Oncology, Surgery, Radiology CAC GF Leclerc, Dijon, France
    Ann Oncol 17:409-14. 2006
  3. ncbi It is time for chronotherapy!
    B Coudert
    Centre Georges Francois Leclerc, 1, rue du Professeur Marion, BP 77980, 21079 cedex, Dijon, France
    Pathol Biol (Paris) 51:197-200. 2003
  4. ncbi Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
    B Coudert
    Centre GF Leclerc BP 77980, 21079 Dijon Cedex, France
    Eur J Cancer 37:2194-8. 2001
  5. ncbi It's time for chronotherapy!
    B Coudert
    Centre Georges Francois Leclerc, 1 rue du Professeur Marion, BP 77980, 21079, Dijon Cedex, France
    Eur J Cancer 38:S50-3. 2002
  6. ncbi Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
    Laurent Arnould
    CLCC G F Leclerc and 1FR100, Dijon, France
    Clin Cancer Res 13:6404-9. 2007
  7. ncbi Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma
    F Vegran
    Centre Georges Francois Leclerc, IFR Santé STIC, Dijon Cedex, France
    Br J Cancer 101:1357-64. 2009
  8. ncbi Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer
    S Lizard-Nacol
    Laboratory of Molecular Genetics, Centre Georges Francois Leclerc, 1 rue du Professeur Marion, 21034 Dijon Cedex, France
    Breast Cancer Res 1:81-7. 1999
  9. ncbi Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues
    P Fumoleau
    Medical Oncology Department, Centre Georges Francois Leclerc, Dijon, France
    Ann Oncol 18:v9-15. 2007
  10. ncbi MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients
    S Lizard-Nacol
    Centre Georges Francois Leclerc, Dijon, France
    Anticancer Res 19:3575-81. 1999

Detail Information

Publications16

  1. ncbi Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial
    Bruno P Coudert
    Department of Oncology, CAC G F Leclerc and IFR 100, Dijon, France
    J Clin Oncol 25:2678-84. 2007
    ..Trastuzumab-based preoperative systemic therapy (PST; neoadjuvant therapy) also appears promising, warranting further investigation...
  2. ncbi Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial
    B P Coudert
    Oncology, Surgery, Radiology CAC GF Leclerc, Dijon, France
    Ann Oncol 17:409-14. 2006
    ..Trastuzumab-based pre-operative systemic (neo-adjuvant) therapy (PST) also appears promising, warranting further investigation...
  3. ncbi It is time for chronotherapy!
    B Coudert
    Centre Georges Francois Leclerc, 1, rue du Professeur Marion, BP 77980, 21079 cedex, Dijon, France
    Pathol Biol (Paris) 51:197-200. 2003
    ....
  4. ncbi Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
    B Coudert
    Centre GF Leclerc BP 77980, 21079 Dijon Cedex, France
    Eur J Cancer 37:2194-8. 2001
    ....
  5. ncbi It's time for chronotherapy!
    B Coudert
    Centre Georges Francois Leclerc, 1 rue du Professeur Marion, BP 77980, 21079, Dijon Cedex, France
    Eur J Cancer 38:S50-3. 2002
    ....
  6. ncbi Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
    Laurent Arnould
    CLCC G F Leclerc and 1FR100, Dijon, France
    Clin Cancer Res 13:6404-9. 2007
    ..Using FISH and IHC, we analyzed the relationship between pathologic complete response to trastuzumab-based neoadjuvant therapy and level of HER-2 amplification in locally advanced breast cancer...
  7. ncbi Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma
    F Vegran
    Centre Georges Francois Leclerc, IFR Santé STIC, Dijon Cedex, France
    Br J Cancer 101:1357-64. 2009
    ..We examined the ability of microarray analyses to determine the potential markers of pathological complete response (pCR)...
  8. ncbi Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer
    S Lizard-Nacol
    Laboratory of Molecular Genetics, Centre Georges Francois Leclerc, 1 rue du Professeur Marion, 21034 Dijon Cedex, France
    Breast Cancer Res 1:81-7. 1999
    ..Furthermore, a GSTM1 isoenzyme has been positively associated with protective effect against mutagenic drugs, such as alkylating agents and anthracyclines...
  9. ncbi Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues
    P Fumoleau
    Medical Oncology Department, Centre Georges Francois Leclerc, Dijon, France
    Ann Oncol 18:v9-15. 2007
    ....
  10. ncbi MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients
    S Lizard-Nacol
    Centre Georges Francois Leclerc, Dijon, France
    Anticancer Res 19:3575-81. 1999
    ....
  11. ncbi Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
    L Arnould
    Department of Pathology, Centre G F Leclerc, Dijon 21000, France
    Br J Cancer 94:259-67. 2006
    ..These results suggest that trastuzumab plus taxanes lead to enhanced NK cell activity, which may partially account for the synergistic activity of trastuzumab and docetaxel in breast cancer...
  12. ncbi Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
    J Y Douillard
    Centre Rene Gauducheau, Saint Herblain, France
    Ann Oncol 16:81-9. 2005
    ..This phase II trial compared docetaxel-cisplatin (DC) with vinorelbine-cisplatin (VC), both as first-line therapy followed by cross-over at progression to single-agent vinorelbine or docetaxel in advanced non-small-cell lung cancer (NSCLC)...
  13. ncbi Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
    S Guiu
    Department of Oncology, Georges Francois Leclerc Cancer Center, F 21000 Dijon, France
    Br J Cancer 103:1335-42. 2010
    ....
  14. ncbi Circadian concepts in normal and neoplastic breast
    B Coudert
    , Dijon, France
    Chronobiol Int 19:221-35. 2002
    ....
  15. ncbi Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study
    N Isambert
    Dept. of Medical Oncology, , Dijon, France
    J Exp Clin Cancer Res 20:183-8. 2001
    ..Total dose of cisplatin in hypotonic glucose solution will not exceed 80 mg by cure in a further phase II study...
  16. ncbi Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells
    B Chauffert
    INSERM, Unite 252, Faculty of Medicine, Dijon, France
    Br J Cancer 56:119-22. 1987
    ..We suggest that amiodarone, which is more efficient and less toxic than verapamil, could be substituted for verapamil in future clinical trials...